Eliem Therapeutics, Inc. (NASDAQ:ELYM – Get Free Report) Director Ra Capital Management, L.P. bought 13,008,546 shares of Eliem Therapeutics stock in a transaction on Thursday, June 27th. The shares were bought at an average cost of $3.84 per share, with a total value of $49,952,816.64. Following the acquisition, the director now directly owns 23,521,757 shares in the company, valued at $90,323,546.88. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Eliem Therapeutics Trading Down 0.8 %
Shares of ELYM stock traded down $0.06 during trading hours on Monday, reaching $7.05. The stock had a trading volume of 43,124 shares, compared to its average volume of 486,386. The stock’s fifty day simple moving average is $7.70 and its 200 day simple moving average is $4.58. Eliem Therapeutics, Inc. has a 12 month low of $2.35 and a 12 month high of $11.55. The firm has a market capitalization of $209.74 million, a PE ratio of -13.30 and a beta of -0.33.
Eliem Therapeutics (NASDAQ:ELYM – Get Free Report) last released its quarterly earnings results on Thursday, March 28th. The company reported ($0.13) earnings per share for the quarter.
Institutional Investors Weigh In On Eliem Therapeutics
About Eliem Therapeutics
Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.
See Also
- Five stocks we like better than Eliem Therapeutics
- Ride Out The Recession With These Dividend KingsĀ
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- High Flyers: 3 Natural Gas Stocks for March 2022
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- Best Stocks Under $10.00
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Eliem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eliem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.